PatentMay 6, 2026, 08:32 AM
CDT Equity's AZD5904 Enters PCT Phase, Seeks Partners
AI Summary
CDT Equity Inc. announced that AZD5904, a potent Myeloperoxidase inhibitor, has progressed into the Patent Cooperation Treaty (PCT) phase, significantly enhancing its global intellectual property protection. The asset has demonstrated a favorable safety profile across five Phase 1 studies with 181 subjects dosed, and CDT holds existing patents for its use in idiopathic male infertility. Leveraging this robust clinical data and expanded global IP strategy, CDT is now actively seeking out-licensing and strategic partnering opportunities to advance AZD5904 into later-stage development, targeting significant unmet medical needs in infertility markets.
Key Highlights
- AZD5904, an inhibitor of human Myeloperoxidase, progressed into the Patent Cooperation Treaty (PCT) phase.
- 181 subjects were dosed across five Phase 1 studies for AZD5904, demonstrating a favorable safety profile.
- CDT holds composition of matter and method of use patents for AZD5904 in idiopathic male infertility.
- The PCT progression enables CDT to pursue broader international IP protection for AZD5904.
- CDT is actively seeking out-licensing and strategic partnering opportunities for AZD5904.
- Promising signals for AZD5904 were identified in idiopathic male infertility and oncology-associated infertility markets.
Price Impact
More from CDT